Skip to main content
Figure 1 | Journal of Hematology & Oncology

Figure 1

From: Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors

Figure 1

Study schema. aAt interim analysis, all patients had received 8 weeks of treatment or discontinued before week 8. bThe final analysis was performed after all patients had received 6 months of study treatment or discontinued treatment before month 6. BC = breast cancer; GC = gastric cancer; NSCLC = non-small cell lung cancer; PK = pharmacokinetic; RCC = renal cell carcinoma.

Back to article page